Background: Rifaximin might decrease the risk of portal hypertension-related com-
Moreover, few medical treatments have been discovered that can prolong overall survival in patients with decompensated cirrhosis, except for aetiology-specific treatment (eg, oral anti-viral treatment for hepatitis B virus-related cirrhosis) 6 or case-specific treatment (eg, nonselective beta-blockers [NSBB] or endoscopic variceal ligation
[EVL] for patients with variceal bleeding). 7, 8 Recently, several studies reported that progressive gut microbiota changes occur in patients with cirrhosis, and these changes may be involved in the pathogenesis of cirrhotic complications. 9, 10 The prevalence of small bowel bacterial overgrowth in patients with cirrhosis is high, ranging between 30% and 70%. 11 The bacterial overgrowth may increase intestinal permeability and translocation, as well as increase levels of endotoxin and circulating pro-inflammatory cytokines, which may contribute to the pathogenesis of portal hypertension-related cirrhotic complications. 12, 13 In this context, oral antibiotics might help to reduce the small intestinal bacterial overgrowth, possibly preventing cirrhotic complications. A prospective study reported that selective intestinal decontamination with a fluoroquinolone, norfloxacin, is effective for preventing a recurrence of SBP. 14 However, there is concern that widespread prophylaxis with norfloxacin might lead to the development of antibiotic-resistant bacteria since norfloxacin is a systemic antibiotic.
Rifaximin, a semisynthetic derivative of rifamycin, is minimally absorbed into systemic circulation and has broad-spectrum in vitro activity against both aerobic and anaerobic enteric bacteria. It has a low risk of inducing systemic bacterial resistance. 15, 16 Therefore, we postulated that rifaximin might decrease the risk of portal hypertension-related complications in patients with cirrhosis regardless of underlying aetiology, which might increase survival in patients with advanced cirrhosis. In fact, a recent randomised, double-blind clinical trial showed that rifaximin maintained remission from HE and reduced the risk of HE-related hospitalisation. 17 Moreover, a recent open-label maintenance study confirmed the safety and efficacy of rifaximin for reducing the risk of HE recurrence. 18 However, the overall effect of rifaximin in patients with cirrhosis has not been fully evaluated in a large-scale cohort.
In this study, we aimed to evaluate whether rifaximin could prolong overall survival and reduce the risks of various cirrhotic complications, other than hepatic encephalopathy (HE), in patients with decompensated cirrhosis.
| MATERIAL AN D METHODS

| Patients
We conducted a retrospective cohort study. Initially, we enrolled 1467
consecutive patients who were diagnosed with cirrhosis-associated HE and recovered after medical treatment at a single tertiary hospital (Seoul National clinician's decision. Then, the rifaximin group comprised all patients, with or without HCC, who were treated with rifaximin (600 mg twice a day) and lactulose (30-60 mL 3 times a day); the control group comprised all patients treated with lactulose only. The physicians instructed patients to achieve the titration target with lactulose so that patients had 2-3 semiformed stools/day for prevention of recurrent HE. The dose of lactulose was assessed during every clinic visit.
Cirrhosis was diagnosed on the basis of clinical findings: (i) platelet count of less than 100 000/lL and ultrasonography findings suggestive of cirrhosis, including a blunted, nodular liver edge accompanied by splenomegaly (bipolar diameter >12 cm) or (ii) clinical signs of portal hypertension, such as ascites, oesophageal or gastric varices, and HE. 19 The presence of ascites was confirmed with abdominal ultrasound or computed tomography (CT) and varices were evaluated by oesophagogastroduodenoscopy or abdominal dynamic CT.
HE was diagnosed on the basis of neuromuscular signs and the West Haven scale (HE; grade ≥2, remission of HE; grade 0 or 1)
which is based on alterations in the state of consciousness, intellectual function and behavior. Reports of HE including confusion and memory loss in patients were obtained from clinical notes.
| Clinical outcomes and follow-up evaluation
The primary endpoint of our study was overall survival. Secondary endpoints included recurrence of HE and the development of SBP, HRS and variceal bleeding. Definitions of clinical outcomes are provided in Data S1. The index date of follow-up is the date of discharge after full recovery from baseline HE. All outcomes were evaluated at the maximum duration of follow-up. The date of all-cause mortality was obtained from patients' medical records and from the Korean Ministry of Government Administration and Home Affairs.
The date of an event was defined as the first event date from the index date. Medication possession rate was calculated by the total days of medication supply divided by time interval. We used a Medication possession rate cutoff value for adherence of >80%. 
| Statistical analyses
We analysed the non-HCC and HCC cohorts separately and used the chi-square test and the independent t-test to evaluate the differences in clinical variables between the rifaximin group and the lactulose group. We used Cox proportional hazards models to assess the influence of the clinical variables on endpoints. For the multivariate analysis, we included covariates with P < .05 in the univariate analysis.
We calculated the cumulative rates of overall survival, HE recurrence, SBP development, HRS and variceal bleeding using the Kaplan-Meier method and censoring the patients who were lost to follow-up. We performed the log-rank test to compare the differences between the groups.
We used inverse probability weighting based on the propensity score to adjust for differences in baseline characteristics. 21, 22 We calculated a propensity score for each patient using a logistic regression model that included the baseline characteristics. The 2 groups were balanced using an inverse probability weight for each patient, which was generated on the basis of the propensity score (Table S1 ). After performing inverse probability weighting, we assessed the balance of baseline characteristics between the groups, and then we fit weighted Cox proportional hazards models.
For statistically significant primary outcomes, the number needed to treat (NNT) was calculated using 1/risk difference. A P < 0.05 was considered statistically significant. The statistical analyses were 3 | RESULTS
| Baseline characteristics
This study involved 421 patients without HCC (the non-HCC cohort) and 621 patients with HCC (the HCC cohort). Among 421 patients of the non-HCC cohort, 145 patients received a combination of rifaximin and lactulose (the rifaximin group) and 276 received lactulose alone (the control group). These 2 groups did not differ in mean age, sex distribution or aetiology of liver cirrhosis (Table 1A) . At baseline, the proportion of patients experiencing previous HE was higher in the rifaximin group than in the control group (31.7% vs 22.1%, P = 0.04). The Child-Turcotte-Pugh score was not significantly different between the groups.
In the HCC cohort (n = 621), 173 patients received a combination of rifaximin and lactulose (the rifaximin group) and 448 received lactulose alone (the control group). Baseline characteristics were similar in the 2 groups, except that the proportion of patients with a previous episode of HE was higher in the control group (Table 1B) .
The Child-Turcotte-Pugh score and TNM stage were not significantly different between the groups. The proportions of patients with varices at baseline, and who received prophylactic treatment (ie, EVL or NSBB) did not differ significantly between the groups in both non-HCC and HCC cohorts.
The prevalence of portal vein thrombosis (PVT) was also comparable between the groups among both non-HCC and HCC cohorts. Most patients with chronic hepatitis B were treated with an anti-viral agent according to the international practice guidelines. 23, 24 Medication possession rate of the rifaximin exceeded 80%, which indicates good adherence to drug, in both the HCC and non-HCC cohorts.
| Overall survival
In the non-HCC cohort, 210 (49.8%) patients died during the followup period: 53 in the rifaximin group and 157 in the control group. (Tables 2A and S2A) .
A cost-effectiveness analysis showed that 9.6 patients would need to be treated with rifaximin to increase the survival rate of 1 patient each year (ie, NNT = 9.6). The cost of rifaximin for 1 year was $7440. For patients without HCC, the 1-year incremental cost to increase survival in 1 patient experiencing HE was $71 424.
In the HCC cohort, 501 (80.6%) patients died during the follow- (Tables 2B and S2B ).
In the entire cohort (n = 1042), rifaximin treatment was significantly associated with lower risk of death even after adjusting for the interaction term before and after inverse probability weighting (P = .047 and .036 respectively) (Table S3 ).
| Complications of portal hypertension
In the non-HCC cohort, 115 patients experienced HE recurrence after recovery of baseline HE: 23 in the rifaximin group and 92 in the control group. The rifaximin group showed a significantly lower risk of recurrent HE than the control group (HR, 0.449; 95% CI, 0.284-0.711; P < .001) ( Figure 3 , left upper panel). In the multivariate analysis, rifaximin treatment was an independent negative risk factor for HE recurrence (aHR, 0.452; 95% CI, 0.286-0.715; P < .001) (Table 2A ). These data suggest that 6.1 patients would need to be treated with rifaximin to prevent an episode of recurrent HE for 1 year (ie, NNT = 6.1).
During the follow-up period, 128 patients without HCC devel- (Table 2A ). These data suggest that 5.4 patients would need to be treated with rifaximin to prevent SBP for 1 year (ie, NNT = 5.4).
A total of 64 patients without HCC experienced variceal bleeding: 11 (7.5%) in the rifaximin group and 53 (19.2%) in the control group.
During the follow-up period, patients who received rifaximin had a significantly lower probability of variceal bleeding than patients in the control group (HR, 0.402; 95% CI, 0.210-0.770; P = .006) (Figure 3 , left lower panel). In the multivariate analysis, rifaximin treatment (aHR, 0.425; 95% CI, 0.220-0.821; P = .011) was an independent negative risk factors of variceal bleeding in the non-HCC cohort after adjustment for the presence of varices, prophylactic treatment (EVL or NSBB) and baseline ALT level (Table 2A ). These data suggest that (Table 2B ). These data suggest that 3.7 patients would need to be treated with rifaximin to prevent SBP for 1 year (ie, NNT = 3.7).
A total of 105 patients with HCC developed variceal bleeding: (Table 2B ). The rifaximin group showed a trend towards a lower risk of developing of HRS than the control group in the HCC cohort, but the difference was not statistically significant (HR, 0.812; P = .292) (Figure 4 , right lower panel).
In the entire cohort, the associations between rifaximin treatment and clinical outcomes, including recurrence of HE (P < .001), SBP (P < .001) and variceal bleeding (P = .001), were significant (Table S4A ).
| Inverse probability weighting analysis
In the non-HCC cohort, the baseline characteristics, including the proportion of patients with a previous episode of HE, became more balanced between the groups after adjustment using inverse probability weighting (Table S1A ). In the multivariate weighted Cox regression analysis, rifaximin was significantly associated with lower risk of death (aHR, 0.718; 95% CI, 0.520-0.992; P = .044) and reduced of recurrent HE (aHR, 0.461; 95% CI, 0.288-0.740; P = .001), SBP (aHR, 0.222; 95% CI, 0.114-0.435; P < .001), and variceal bleeding (aHR, 0.387; 95% CI, 0.197-0.758; P = .006) but not HRS (aHR, 0.568; P = .057) (Table S5A ). F I G U R E 2 Kaplan-Meier estimates of overall survival according to treatment group. The solid lines represent overall survival in the rifaximin group and the dotted lines represent overall survival in the control group. A, In the non-HCC cohort, the rifaximin group showed significantly higher overall survival than the control group. B, In the HCC cohort, the rifaximin group showed similar overall survival to the control group
In the HCC cohort, the baseline characteristics became more balanced between the groups after adjustment using inverse probability weighting (Table S1B ). In the multivariate weighted Cox regression analysis, rifaximin was not related to lower risk of death (aHR, 1.213; P = .073) (Table S5B) (Table S5B ).
In the entire cohort, the associations of rifaximin treatment with clinical outcomes, including overall survival (P = .036), HE (P < .001), SBP (P < .001), and variceal bleeding (P = .028), were confirmed after inverse probability weighting (Tables S3B and S4B ).
| Adverse events
Eight patients developed the C. difficile-associated diarrhoea during follow-up period: 1 patient in the rifaximin group and 7 in the control group. The risk of C. difficile-associated diarrhoea was not significantly different between the groups (P = .338).
Of the 355 patients with development of SBP, positive ascites cultures were detected in 39 (11.0%) patients: 11 in the rifaximin group and 28 in the control group (Table S6 ). All cases of SBP in the rifaximin group were associated with infection with Gram-negative bacteria. In the control group, Gram-negative bacteria were isolated from 25 cases and Gram-positive bacterial infections were reported in 3 cases. Child Our study demonstrated that rifaximin treatment was associated with lower risk of death in the non-HCC cohort, which was confirmed by both Cox proportional hazards models and inverse probability weighting. Until now, only several small short-term studies have reported the effect of rifaximin treatment in patients with cirrhosis.
T A B L E 2 Variables independently associated with endpoints in patients with and without hepatocellular carcinima (HCC)
One study showed that the 5-year cumulative probability of survival was higher in patients receiving rifaximin (n = 23) than in patients not receiving rifaximin (n = 46). 25 These results are consistent with our study. However, that study had a small sample size and compared the rifaximin group with a placebo group, not a lactulose group, as in our study. In a previous study, efficacy of rifaximin for improving survival also was showed in patients with cirrhosis. A significant decrease in short-term mortality for 10 days after treatment was evident in patients who received lactulose plus rifaximin compared to patients who received lactulose alone. 26 The study was limited by a short-term follow-up period. In contrast, the median follow-up duration was 18.0 months in our study and we demonstrated rifaximin's effect on overall survival during a longer follow-up period than the previous study. We also evaluated the effect of rifaximin on survival in patients with HCC. Unlike the results in the non-HCC cohort, rifaximin treatment was not associated with the risk of death in the HCC cohort. There were no changes in the results after adjusting for TNM stage, which is known to be the most important prognostic factor in HCC. 27 This may indicate that the tumour itself has a greater impact on survival than cirrhotic complications in patients with HCC. Small intestinal bacterial overgrowth in cirrhotic patients is common and is associated with systemic endotoxemia, which leads to further worsening of portal hypertension. 28 In a previous study, concomitant rifaximin and lactulose significantly affected the mucosal microbiota composition compared with lactulose alone. 29 A prospective study also showed that rifaximin reduces levels of endotoxins, such as lipopolysaccharide, and improves systemic inflammation in cirrhotic patients. 30 These data suggest that rifaximin may contribute to the control of gut microbiota imbalance and act as an important therapeutic agent for controlling small intestinal bacterial overgrowth. These modulatory activities on gut microbiota bacterial composition may underline the efficacy of rifaximin for gut-derived toxins that contribute to the development of complications of cirrhosis. 31 This effect might improve liver hemodynamics and associate with lower risk of death.
In non-HCC cohort, our study clearly demonstrated that rifaximin had additive effects compared to lactulose alone for reducing the risks of recurrent HE and SBP. Small intestinal bacterial overgrowth and bacterial translocation are mainstays of SBP development. Therefore, it has been hypothesised that rifaximin, being effective on small intestine bacterial overgrowth, could be beneficial in preventing SBP.
Indeed, our study also showed that lower risk of SBP was associated with rifaximin. Rifaximin treatment was also an independent factor for preventing variceal bleeding in our study. A previous study reported that rifaximin treatment reduced endotoxin levels and associated with a decreased hepatic venous pressure gradient. 31 It is well accepted that reduction in portal pressure (below 12 mm Hg) prevents variceal bleeding. 32, 33 However, rifaximin was not confirmed to reduce the risk of HRS. Although rifaximin may reduce endotoxemia through a beneficial modulation of gut microbiota, rifaximin was not related with the risk of developing HRS, possibly because HRS has a multifactorial pathophysiology, except for endotoxemia.
In the HCC cohort, rifaximin treatment was less effective in reducing the risk of cirrhotic complications, except for SBP, than in the non-HCC group. The Child-Turcotte-Pugh score was not significantly different between non-HCC group and HCC group in our study (P = .158). Previous studies reported that HCC was an independent factor that contributed to the poor prognosis of HE. 34, 35 Concentrations of aromatic amino acids were reported to be higher in patients with HCC than in patients without HCC, which suggests that the imbalance of aromatic and branched amino acids are related to the development of HE in patients with HCC. 36 The presence of HCC was speculated to synergistically influence poor outcomes in HE and reduce the effect of rifaximin in preventing recurrent HE.
Our study also showed that rifaximin treatment was not an independent negative risk factor for variceal bleeding in patients with HCC.
We assume that portal vein thrombosis was distributed unevenly between patients with HCC and without HCC. Previous studies have associated the presence of portal vein thrombosis with negative outcomes in variceal bleeding. 37 In our study, the impact of rifaximin treatment on overall survival of the non-HCC and HCC cohorts differed ( Figure S1 ). The interaction plot indicated a significant interaction between the presence of HCC and the impact of treatment regimens on overall survival (Figure S2 ). In the entire cohort, the beneficial effect of rifaximin treatment on overall survival still remained even after consideration of the interaction. We evaluated the cost-effectiveness of rifaximin by calculating the NNT and the incremental costs per patient ($7440/ year) relative to the control group. The 1-year incremental cost was $85 560 to increase the survival rate in one patient without HCC.
The 1-year incremental cost ranged from $47 616 to $69 936 to prevent portal hypertension-related complications. Therefore, with consideration given to the economic situation of each country, rifaximin treatment can be recommended for patients with cirrhosis to decrease the costs incurred by most health care systems.
The major limitation of our study is that it was based on retrospective observational data. Thus, we performed the multivariate Cox regression analysis with and without inverse probability weighting to balance the baseline characteristics. After the multiple regression and inverse probability weighting analyses, rifaximin consistently showed significant associations with increased overall survival rates and reduced portal hypertension-related complications. Moreover, it may be unethical to launch a prospective clinical trial comparing rifaximin to a control group because rifaximin is already a standard treatment for patients who experience HE in clinical practice. Second, this study enrolled patients at high risk for portal hypertension-related complications who already had experienced HE and had advanced cirrhosis.
Moreover, more than half of the patients with HCC (54.3%) had
Child-Turcotte-Pugh class C cirrhosis and therefore in Barcelona
Clinic Liver Cancer stage D. This might explain why our HCC study cohort experienced a higher incidence of endpoints, including a 65% mortality month 12, than reported in previous studies. There might be a selection bias because our study cohort consisted of patients at tertiary referral centre who had advanced or recurrent HCC, which are associated with worse outcomes. Our study could provide favourable evidence to launch a randomised clinical trial in patients who have decompensated liver cirrhosis and no previous HE event.
The strengths of the present study include the fact that the data were obtained from a large number of patients. Although there was missing data including ECOG status known to be one of the important predictor of outcome in HCC patients in our retrospective observational study, this is the first study evaluating the effect of rifaximin in patients with HCC. Nevertheless, because this is a retrospective observational study, it could only demonstrate associations between rifaximin treatment and various clinical outcomes, including overall survival. Therefore, further studies, such as randomised prospective studies, are necessary to clarify the beneficial effects of rifaximin for patients with portal hypertension. In conclusion, the results of our study show that rifaximin treatment was significantly associated with lower risk of death and the risk of developing SBP, variceal bleeding and recurrent HE in patients without HCC.
Although rifaximin was not associated with lower risk of death in patients with HCC, it has been shown to be related to preventing portal hypertension-related complications. This study may support the initiation of a large cohort study to assess the overall efficacy of rifaximin in patients with previous HE.
